Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello A, Mastio F, Bartalena L, Martino E
Istituto di Endocrinologia, Università di Pisa, Italy.
J Endocrinol Invest. 1993 Jul-Aug;16(7):541-3. doi: 10.1007/BF03348901.
The somatostatin analogue, octreotide (OC) has commonly been used in the management of growth hormone- and thyrotropin-secreting pituitary tumors, and shown to be effective both on hormone production and tumor size. Because OC receptors may be expressed also in some nonfunctioning pituitary adenomas, it has been postulated that OC might play a role in the treatment of these tumors as well. In the present study, the morphological effects of OC administration, as assessed by computer tomography (CT) scan, were evaluated in 8 patients (5 men, 3 women, age range 25-79 yr) affected by non-functioning pituitary tumors. The drug was given sc at the dose of 100 micrograms tid for 3-6 months. No significant change in visual field or tumor size occurred after OC treatment in 7 patients, whereas one showed a significant improvement of visual field associated with a decreased tumoral mass. These data suggest that OC is not an effective drug in the management of nonfunctioning pituitary adenomas.
生长抑素类似物奥曲肽（OC）常用于治疗分泌生长激素和促甲状腺激素的垂体肿瘤，且已证明其对激素分泌和肿瘤大小均有疗效。由于OC受体也可能在一些无功能垂体腺瘤中表达，因此推测OC在这些肿瘤的治疗中可能也发挥作用。在本研究中，通过计算机断层扫描（CT）评估了8例（5例男性，3例女性，年龄范围25 - 79岁）无功能垂体肿瘤患者使用OC后的形态学效应。药物以100微克皮下注射，每日3次，持续3 - 6个月。7例患者在接受OC治疗后视野和肿瘤大小无明显变化，而1例患者视野显著改善，同时肿瘤体积减小。这些数据表明，OC在治疗无功能垂体腺瘤方面并非有效药物。
